TotalMarketCap

Lycia Therapeutics

LYCANasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.503 B

$28.85 -3.83%

Close of 27 Oct 2026

As of 27 Oct 2026, Lycia Therapeutics (LYCA) has a market capitalization of $1.50B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

—

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #39ImmunocoreIMCR$1.61B
  2. #40NovavaxNVAX$1.55B
  3. #41Lycia TherapeuticsLYCA$1.50B
  4. #42Taysha Gene TherapiesTSHA$1.31B
  5. #43Inhibrx BiosciencesINBX$1.30B

What if Lycia Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.1T

$539,781.51

Per share 18,710× higher

Bitcoin $1.63T

$31,201.09

Per share 1,081× higher

Nvidia $5.21T

$99,925.98

Per share 3,464× higher

Or at a round number

$2.00B$5.00B$10.0B$20.0B

Where these numbers come from

Share counts and financials for Lycia Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 28 Oct 2026. Read the methodology.